Nanjing Medlander Medical Technology Co. Ltd. A (688273) — Capital Reinvestment Ratio
Nanjing Medlander Medical Technology Co. Ltd. A (688273) has a Capital Reinvestment Ratio of 1.06x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥122.51 Million) in capital expenditures (CN¥129.71 Million). See cash generation quality of Nanjing Medlander Medical Technology Co. to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Medlander Medical Technology Co. Ltd. A Capital Reinvestment Ratio (2020–2024)
This chart tracks Nanjing Medlander Medical Technology Co. Ltd. A's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)
Year-by-year Capital Reinvestment Ratio for Nanjing Medlander Medical Technology Co. Ltd. A from 2020 to 2024. For live market cap and broader valuation context, see Nanjing Medlander Medical Technology Co. (688273) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.06x | CN¥122.51 Million | CN¥129.71 Million | ▲ +92.9% |
| 2023 | 0.55x | CN¥136.91 Million | CN¥75.15 Million | ▲ +28.1% |
| 2022 | 0.43x | CN¥126.67 Million | CN¥54.26 Million | ▲ +336.4% |
| 2021 | 0.10x | CN¥148.60 Million | CN¥14.58 Million | ▼ -50.3% |
| 2020 | 0.20x | CN¥131.10 Million | CN¥25.91 Million | — |